About Cellphire


Cellphire, Inc. is a biotechnology company established in early 2006. The company focus is on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cutting edge cell stabilization technology. With its origins in bio-defense, Cellphire is commercializing freeze dried platelet derived products with an initial focus on applications within the global blood & blood supply markets.

Cellphire is developing technology and products with application in diverse health care fields from transfusion, advanced wound care (chronic & acute) to clinical & research diagnostic reagents.

The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt the constant supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties.

Message from the CEO:

The underlying technology that Cellphire has developed promises to provide a quantum leap forward in how cells are handled and used within health care today. Our initial application, platelets, is a perfect example. Untreated platelets last five days outside of a donor’s body: with our patented treatment, we are able to freeze dry platelet derived products for storage measured in years, at room temperature. Reconstitution is as simple as adding sterile water.

With the support of the Biomedical Advanced Research Defense Authority (BARDA), a division of U.S. Department of Health & Human Services, and their $57 million grant to us, we have the ability and resources to take this product far down the road through a Phase 2 clinical trial and eventually FDA approval. BARDA is interested because this product has the potential to be the first and only product to remediate a key problem caused by exposure to radiation. Our reconstituted freeze dried platelets (Thrombosomes®) have been shown, in animals, to have profound benefits in wound healing. Thromobosomes® have the potential to be powerful imaging agents; to assist in sports medicine, plastic surgery, dentistry; as well as a host of other applications. Our underlying cell stabilization technology has application to other cell types as well.

Our fundamental mission is to obtain FDA approval of Thrombosomes® as a hemostatic agent to stop active bleeding in surgical or thrombocytopenic patients while BARDA’s interest is in the use of Thrombosomes® for treatment of acute radiation sickness. We can pursue other applications as well, because the same technology is used in each of them. To do them as well, we will seek additional partners in each related field. By continuing our unique ability to stabilize cells with leading companies in key therapeutic areas, we seek to make a major difference in health care in the United States and around the world.

Stephen H Willard




Stephen H. Willard - Chief Executive Officer and Director
Before joining Cellphire in 2013, Mr. Willard served as CEO and Chairman of the Board of Flamel Technologies, a NASDAQ-traded biotech company with a market capitalization in excess of $1 billion under his leadership.  He has served as Chief Financial Officer and General Counsel of publically traded companies, as well as an investment banker and attorney in private practice.  He served as a director of E*Trade Bank and E*Trade Financial Corporation for a total of 14 years, including a period as Vice Chairman.  He received a B.A, from Williams College and a Juris Doctorate from Yale Law School.  He is currently a member of the National Science Board.

G. Michael Fitzpatrick - Ph.D., President & Director of R&D
Dr. Fitzpatrick has been at Cellphire since 2007 and has led the development of its first line of hemostatic products. He has over 40 years of blood banking and biomedical experience.   He previously served as Chief Operating Officer of America's Blood Centers (“ABB”), North America's largest network of 75 non-profit, community blood centers.  ABB operates more than 600 collection sites in the U.S. and Canada, providing nearly half of the United States, and nearly one-quarter of Canada's, volunteer donor blood supply.  These centers serve more than 150 million people and provide blood products and services to more than 3,300 hospitals.  Prior to ABC, Dr. Fitzpatrick was a Colonel in the U.S. Army and the Director of the Armed Services Blood Program (1999- 2003).  As part of his 28-year military career, his assignments included: Korea Area Blood Program Officer; United States European Command Blood Program Officer; Chief of the Blood Bank at Madigan Army Medical Center; Tripler Army Medical Center; and Walter Reed Army Medical Center.  He also has served as the director of the Tri-Service Blood Bank Fellowship at Walter Reed.  Dr. Fitzpatrick is a member of the AABB Inter-Organizational Task Force on Disaster Response and the AABB FDA-Liaison Committee.

Rafael Jorda - Executive Vice President
Rafael Jorda is an international scientific leader with more than 25 years of experience in private and public company management spanning 3 continents. Specifically, Rafael Jorda has managed the Research and Development, Intellectual Property, Production, and Business Development operations of pharmaceutical and biotechnology companies. Rafael is a co-founder of Flamel Technologies (FLML) and, leading its research and manufacturing departments, built Flamel into a public company. Previously, Rafael worked in the polymer research group of Rhône-Poulenc. Rafael holds a Masters of Science in Chemical Engineering from Virginia Polytechnic Institute and State University.

Anne Hale, DMV - Chief Technical Officer, BodeVet, Inc. (Cellphire veterinary subsidiary)
Dr. Hale is a renowned expert in veterinary transfusion medicine. She earned an NIH Comparative Fellowship in Transfusion Medicine. Dr. Hale founded and guided Midwest Animal Blood Services, an internationally known blood bank.  She worked as the CEO and Director for Animal Blood Resources International while the company launched a new line of lyophilized blood products. Dr. Hale is currently CSO of The Platelet Farm, managing the research and commercialization of veterinary blood products (included freeze-dried equine platelet lysate). In addition, Dr. Hale held a position as an internist at the Veterinary Emergency and Specialist Centers in New Mexico before joining BodeVet.   She is a founding member of the American Association of Veterinary Blood Banks and is an active member of many other like organizations including the American Veterinary Medical Association, the North American Veterinary Regenerative Medicine Association, and the Association of Veterinary Hematology and Transfusion Medicine.  Dr. Hale is also a trustee for The Pet Blood Bank UK.

Thomas S. Dann - Chief Investment Officer
Mr. Dann has almost 20 years’ experience in technology investing and company building. He was previously Managing Director of two early stage venture funds, the Maryland Venture Fund and ECentury Capital Partners.  Mr. Dann also formerly served as a director of Global Internet Ventures, LLC and as Founder and Managing Director of Castlehaven Advisors, LLC.  During his venture career, he served as a director of numerous early stage companies as well as a Director of the Mid-Atlantic Venture Association. Mr. Dann received a B.A. degree from Stanford University and a Juris Doctorate from American University Law School.

Keith A. Moskowitz, Ph.D. MPM - Vice President of Discovery
Dr. Moskowitz has spent 20 years in technical, management and positions in the areas of hemostasis and thrombosis, infectious and genetic diseases.  His work includes laboratory and POC diagnostics, medical devices, biologicals and custom laboratory services. He has been responsible for domestic and international regulatory and distribution channels, OEM, government grants and contracts, cGMP and GLP and has taken several products from idea to market. He is the author of over four dozen peer reviewed publications, abstracts and patents and is a member of the American Society of Hematology, The American Society of Clinical Chemistry, The International Society for Hemostasis and Thrombosis, the American Academy of Project Management, The American Association for Clinical Chemistry and the American Association of Clinical Pathologists.

Mike Stanton - Chief Operating Officer
Mike Stanton has been at Cellphire since Jan 2014. His background includes extensive experience in both blood bank administration with strong technical, regulatory and quality skills, and in clinical information systems, to include Quality System Regulations, medical device 510(k) development and submission, as well as Management Representative for medical device manufacturing. Mike was a Lieutenant Colonel in the US Army.  He is a registered Medical Technologist with a Specialist in Blood Bank certification and holds a Bachelor of Science degree from University of Illinois Chicago and a Master of Science Degree from the University of Cincinnati, College of Medicine.

Thomas Landro - Director of Program Management
Thom Landro is the Director of Program Management at Cellphire and is the Program Manager for Cellphire’s BARDA contract for the development of Thrombosomes®. Mr. Landro joins Cellphire after 15 years of program, portfolio and alliance management experience in the pharmaceutical, biotech, and medical device industries. Recent experience includes serving as Director of Strategic Technical Alliances at Novavax, Inc. and was the Program Manager for Medimmune’s BARDA contract for the development of Cell Culture Derived Seasonal and Pandemic Influenza Vaccines. Thom is PMP Certified and holds a Bachelor of Science in Chemical Engineering at the University of Utah and an MBA from the University of Michigan.

Nigel J McWilliam - VP Business Development
Before joining Cellphire, he was V.P. Business Development of Flamel Technologies, Inc. From 1999 to 2003, he established a business development group in the USA and Japan for SkyePharma as Senior V.P.Business Development. His career began with 18 years with Dow Corning Corporation in commercial roles within their health care businesses in the UK, Belgium, France, and the U.S.  He is a graduate of the Dundee University, Scotland, B.Sc. Physiology & Psychology.

Ruth Biehl - Quality Assurance Director
Ruth Biehl has been at Cellphire since November 2013. Her early experience encompassed clinical laboratory testing, genetic engineering research, and operations research.  Since 1990 she has focused on FDA compliance remediation, quality systems design and implementation, quality systems auditing, establishing procedures for drug and medical device manufacturer’s management of clinical trials, and monitoring clinical trials.  She is a registered Clinical Laboratory Scientist (ASCP) and licensed Medical Laboratory Scientist (California).  She is certified by ASQ as a Manager of Quality/Organizational Excellence and as a Quality Engineer.  She is certified by the Association of Clinical Research Professionals as a Certified Clinical Research Associate (CCRA).  Ruth is also an IRCA-certificated ISO 9000 quality management systems auditor.  She holds a Bachelor of Science degree from Oregon State University, a Master of Science from the University of Arizona, and a Master of Business Administration from Southern Illinois University at Edwardsville.


John Ludwig Vogelstein (Chairman)
Mr. Vogelstein was a co-founder of Warburg, Pincus LLC and remains a special limited partner.  For more than 30 years, he served as President of Warburg, Pincus.  Prior to joining Warburg, Mr. Vogelstein was a partner of Lazard Freres & Co. He is chairman emeritus of the New York City Ballet and of Prep for Prep; chairman of Third Way; vice chairman of the board of overseers of The Leonard N. Stern School of Business at New York University; trustee of New York University; trustee of Temple Emanu-El; and a life trustee of The Jewish Museum. He attended Harvard College.

James B. Peake, MD, Lt. Gen. (Ret.)
General Peake is Senior Vice President of CGI Federal. Previously he served as U.S. Secretary of Veterans Affairs.  He is a retired U.S. Army Lieutenant General and served as the Army Surgeon General. As Army Surgeon General, Dr. Peake commanded 50,000 medical personnel and 187 army medical facilities worldwide. Prior to that, he served as Commanding General of the U.S. Army Medical Department Center and School, one of the largest medical training facilities in the world with 30,000 students annually. In addition, he was the Executive Vice President and Chief Operating Officer of Project Hope.  Dr. Peake received his Bachelor of Science degree from U.S. Military Academy at West Point in 1966.  Following service in Vietnam with the 101st Airborne Division, where he was awarded the Silver Star, a Bronze Star with “V” device and the Purple Heart with oak leaf cluster, Dr. Peake received his medical doctorate from Cornell University.

Rodman W. Moorhead III
Mr. Moorhead retired from Warburg Pincus, a global private equity firm, after a career spanning 37 years. His last position at Warburg Pincus was as Senior Advisor and Managing Director of their Life Sciences practice. He is Chairman of the Board of The Taft School, a member of the Harvard Medical School Board of Fellows, Chairman of Stroud Water Research Center, trustee of the Brandywine Conservancy and trustee of the Jackson Hole Land Trust. Mr. Moorhead holds an AB in Economics from Harvard College and an MBA from Harvard Business School.

David I. Hirsh, Ph.D.
Dr. Hirsh is a Professor in the Department of Biochemistry and Molecular Biophysics at the College of Physicians and Surgeons of Columbia University.  He has served as Chairman of the Department and as Executive Vice President of Research at Columbia University.  Dr. Hirsh also worked as the Executive Vice President and Director of Research at Synergen Inc. He is Chairman of the Board of the New York Structural Biology Center and a Member of the Boards of Rockefeller University and the Agouron Institute.  He formerly served as the Chairman of Life Sciences Advisory Board at Warburg Pincus LLC. and as a Director of several biotechnology companies.  He received a B.A. degree from Reed College, a Ph.D. degree in Biochemistry from Rockefeller University and did postdoctoral studies at the Medical Research Council in Cambridge, England. 


Dr. John Crowe, Professor Emeritus UC-Davis
Dr. Tim Hannon, Medical Director Blood Management Program, St. Vincent’s Hospital
Dr. Steven Gould, former CEO Northfield

Have Questions?Reach us here

Please enter your information below

The Cellphire Method

Cellphire has developed a proprietary method for the stabilization of blood cells in the dry state. The first application of this technology is to develop long term stabilization of platelets as a hemostatic agent.